248 related articles for article (PubMed ID: 15857537)
21. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
22. Recombinant factor VIIa in the treatment of bleeding.
Midathada MV; Mehta P; Waner M; Fink LM
Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
[TBL] [Abstract][Full Text] [Related]
23. Primary use of the venovenous approach for extracorporeal membrane oxygenation in pediatric acute respiratory failure.
Pettignano R; Fortenberry JD; Heard ML; Labuz MD; Kesser KC; Tanner AJ; Wagoner SF; Heggen J
Pediatr Crit Care Med; 2003 Jul; 4(3):291-8. PubMed ID: 12831409
[TBL] [Abstract][Full Text] [Related]
24. Novoseven use in a non-cardiac pediatric ECMO patient with uncontrolled bleeding.
Preston TJ; Olshove VF; Ayad O; Nicol KK; Riley JB
J Extra Corpor Technol; 2008 Jun; 40(2):123-6. PubMed ID: 18705548
[TBL] [Abstract][Full Text] [Related]
25. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
26. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
Udy A; Vaghela M; Lawton G; Sigston P
Anaesthesia; 2005 Jun; 60(6):613-6. PubMed ID: 15918835
[TBL] [Abstract][Full Text] [Related]
27. [Emergency use of extracorporeal membrane oxygenation in pediatric critically ill patients].
Lin R; Zhang CM; Tan LH; Shi LP; Xiong QX; Zhang EW; Shu Q; Du LZ
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):649-52. PubMed ID: 23158812
[TBL] [Abstract][Full Text] [Related]
28. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII.
Veldman A; Fischer D; Voigt B; Beyer PA; Schlösser R; Allendorf A; Kreuz W
Intensive Care Med; 2002 Nov; 28(11):1635-7. PubMed ID: 12415453
[TBL] [Abstract][Full Text] [Related]
29. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
[TBL] [Abstract][Full Text] [Related]
30. Extracorporeal membrane oxygenation for refractory septic shock in children: one institution's experience.
Maclaren G; Butt W; Best D; Donath S; Taylor A
Pediatr Crit Care Med; 2007 Sep; 8(5):447-51. PubMed ID: 17693912
[TBL] [Abstract][Full Text] [Related]
31. Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Jen H; Shew S
J Pediatr Surg; 2008 Dec; 43(12):2235-8. PubMed ID: 19040942
[TBL] [Abstract][Full Text] [Related]
32. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.
Bowles KM; Callaghan CJ; Taylor AL; Harris RJ; Pettigrew GJ; Baglin TP; Park GR
Br J Anaesth; 2006 Oct; 97(4):476-81. PubMed ID: 16914465
[TBL] [Abstract][Full Text] [Related]
33. Recombinant factor VIIa (Novoseven) as a hemostatic agent.
Hedner U
Semin Hematol; 2001 Oct; 38(4 Suppl 12):43-7. PubMed ID: 11735110
[TBL] [Abstract][Full Text] [Related]
34. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.
von Heymann C; Redlich U; Jain U; Kastrup M; Schroeder T; Sander M; Grosse J; Ziemer S; Koscielny J; Konertz WF; Wernecke KD; Spies C
Crit Care Med; 2005 Oct; 33(10):2241-6. PubMed ID: 16215377
[TBL] [Abstract][Full Text] [Related]
35. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy.
Gowers CJ; Parr MJ
Anaesth Intensive Care; 2005 Apr; 33(2):196-200. PubMed ID: 15960401
[TBL] [Abstract][Full Text] [Related]
36. Elective decompression of the left ventricle in pediatric patients may reduce the duration of venoarterial extracorporeal membrane oxygenation.
Hacking DF; Best D; d'Udekem Y; Brizard CP; Konstantinov IE; Millar J; Butt W
Artif Organs; 2015 Apr; 39(4):319-26. PubMed ID: 25327220
[TBL] [Abstract][Full Text] [Related]
37. Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
Fischer D; Schloesser R; Buxmann H; Veldman A
J Pediatr Hematol Oncol; 2008 May; 30(5):337-42. PubMed ID: 18458565
[TBL] [Abstract][Full Text] [Related]
38. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
39. Successful use of extracorporeal membrane oxygenation in severe necrotizing pneumonia caused by Staphylococcus aureus.
Stroud MH; Okhuysen-Cawley R; Jaquiss R; Berlinski A; Fiser RT
Pediatr Crit Care Med; 2007 May; 8(3):282-7. PubMed ID: 17417120
[TBL] [Abstract][Full Text] [Related]
40. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
Tobias JD; Simsic JM; Weinstein S; Schechter W; Kartha V; Michler R
J Intensive Care Med; 2004; 19(5):270-3. PubMed ID: 15358945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
